Effect of Linvemastat in Patients With Partially Controlled Asthma (syMMPonia)

This study explores a potential new treatment for adults with moderate-to-severe asthma using a drug called linvemastat, which targets an enzyme linked to lung inflammation. Despite using standard asthma medications, many patients still struggle with symptoms, so researchers are testing whether linvemastat can improve lung function and reduce flare-ups. In a carefully controlled trial, participants receive either one of two doses of the drug or a placebo, while continuing their usual treatments. Over 16 weeks, scientists monitor breathing capacity, symptom control, and safety to determine if linvemastat could offer a meaningful new option for asthma management.

NCT Number	NCT07191535
Lead Sponsor	Foresee Pharmaceuticals Co., Ltd. Collaborators: QPS Holdings LLC
Conditions	Asthma (Diagnosis), Pulmonary Function, Moderate-to-Severe Asthma
Enrollment	135 participants
Start Date	2027-03-01
Primary Completion	2028-01-01 (estimated)
Study Completion	2028-09-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-20